



September 11, 2024

Nevada Medicaid Web Announcement 3436

Attention All Providers: Healthcare Common Procedure Coding System (HCPCS) Code Q5126 Open for Billing

Effective January 1, 2023, Nevada Medicaid is opening Healthcare Common Procedure Coding System (HCPCS) code Q5126 (Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg) for billing by all providers. Claims must be submitted with a National Drug Code (NDC).

Effective October 1, 2024, prior authorization (PA) will be required.

Claims submitted for HCPCS code Q5126 with dates of service from January 1, 2023, through September 10, 2024, that denied with error code 3001 (Prior authorization not found) will be reprocessed automatically. Results of the reprocessed claims will appear on a future remittance advice.

When claims are reprocessed, please be aware that all system and clinical claim editor edits are applicable. As a result, there may be no additional payment, and other claim denials may be received. Providers have the right to appeal denied claims, including those denied upon reprocessing. Please refer to [Medicaid Services Manual Chapter 100](#) and the [Billing Manual](#) for information concerning the claim appeal process and time frames.